Top Abstract Purchase Related
Home
>
Node
>
Subnode

Current results of chemotherapy in multiple myeloma

Sezaki, T.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(5): 1997-2003

1989

ISSN/ISBN: 0385-0684
PMID: 2658839
Document Number: 334371
Since multiple myeloma has a heterogenous character in its pathophysiology, it is clinically classified according to various kinds of factors. Therefore, in the treatment of multiple myeloma, it is important to select efficacious regimens considering the different progress or modes of the diseases as defined by both Durie and Salmon's staging systems and tumor distribution classifications. In this review, the correlation between the response to chemotherapy and survival was analyzed and demonstrated to be significant when we used new response criteria, namely the serum albumin and M-protein levels after the treatment. The new criteria should be applied to determine a prognosis and improve survival. Recently, there has been progress in treatments involving high-dose melphalan combined with autologous bone marrow transplantation for refractory or relapsed myeloma patients. This treatment is anticipated to prolong survival.

Document emailed within 1 workday
Secure & encrypted payments

Kasili, E.G. 1976: Current trends in chemotherapy of leukaemias lymphomas and multiple myeloma East African Medical Journal 53(9): 554-559
Tribalto, M.; Arcese, W.; Colombo, R.; Pastore, S.; Franchii, A. 1981: Chemotherapy of multiple myeloma. Review of the recent trials Recenti Progressi in Medicina 71(2): 141-147
Alexanian, R.; Migliore, P.J. 1970: Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy Journal of Laboratory and Clinical Medicine 75(2): 225-233
Thomas, P.J.; Daban, A.; Bontoux, D. 1984: Double hemibody irradiation in chemotherapy-resistant multiple myeloma Cancer Treatment Reports 68(9): 1173-1175
Weber, D.M. 2003: Strategies in treating newly diagnosed or untreated multiple myeloma patients. from the Multiple Myeloma Research Foundation Oncology 17(6): 765-767
Alberts, D.S.; Golde, D.W. 1974: DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy Cancer Research 34(11): 2911-2914
Bataille, R.; Morlock, G.; Rosenberg, F.; Sany, J.; Serre, H. 1979: Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 55(31-32): 1377-1382
Kurihara, K.; Hill, W.; Burkhardt, R.; Kettner, G.; Hashimoto, N. 1987: Bone marrow changes following chemotherapy for multiple myeloma--a clinicopathological study of biopsy cases Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 50(4): 876-889
Li, J.; Zhao, Y.; Luo, S.-K.; Huang, B.-H.; Zhang, G.-C.; Peng, A.-H.; Zheng, D.; Su, C.; Xu, D.-R.; Tong, X.-Z.; Gu, J.-L.; Ding, Y. 2008: The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma Zhonghua Yi Xue Za Zhi 88(30): 2140-2143
Morstyn, G.; Schechter, G.P.; Ihde, D.C.; Carney, D.N.; Eddy, J.L.; Cohen, M.H.; Minna, J.D.; Bunn, P.A. 1984: Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness Cancer Treatment Reports 68(12): 1439-1446
Ludwig, H.; Fritz, E. 1981: Individualized chemotherapy in multiple myeloma by cytostatic drug sensitivity testing of colony-forming stem cells Anticancer Research 1(6): 329-334
Golenkov, A.K.; Trifonova, E.V.; Kataeva, E.V.; Kil'diushevskiĭ, A.V.; Lutskaia, T.D.; Zariad'eva, E.A.; Nazarova, I.N.; Lukashina, M.N.; Zabotina, T.N.; Mikhaĭlova, I.N.; Inshakov, A.N.; Logacheva, N.P.; Baryshnikov, A.Iu. 2000: Characteristics of drug resistance of tumor plasmocytes in vitro in patients with multiple myeloma differently responsive to chemotherapy Terapevticheskii Arkhiv 72(8): 38-41
Li, X.; Sun, W.; Jin, F.; Chen, S.; Zhong, Y.; Hu, Y.; Zhang, J.; An, N.; Shen, M.; Huang, Z. 2014: Clinical observation of DECP combination chemotherapy for relapsing and refractory multiple myeloma patients with extramedullary plasmacytomas Zhonghua Yi Xue Za Zhi 94(16): 1258-1260
Dreyfus, F.; Ribrag, V.; Leblond, V.; Ravaud, P.; Melle, J.; Quarre, M.C.; Pillier, C.; Boccaccio, C.; Varet, B. 1995: Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma Bone Marrow Transplantation 15(5): 707-711
Bessmel'tsev, S.S.; Abdulkadyrov, K.M. 2002: Results, failures and perspectives in therapy of multiple myeloma Voprosy Onkologii 48(2): 146-152
Chanukuppa, V.; Taware, R.; Chatterjee, T.; Sharma, S.; More, T.H.; Taunk, K.; Kumar, S.; Santra, M.K.; Rapole, S. 2018: Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma Current Topics in Medicinal Chemistry 18(30): 2584-2598
Kumar, L.; Boya, R.R.; Pai, R.; Harish, P.; Mookerjee, A.; Sainath, B.; Patekar, M.B.; Sahoo, R.K.; Malik, P.S.; Sharma, O.D.; Gupta, R. 2016: Autologous stem cell transplantation for multiple myeloma: Long-term results National Medical Journal of India 29(4): 192-199
Palumbo, A.P.; Garino, A.L.; Frieri, R.; Gallone, G.; Boccadoro, M.; Pileri, A. 1990: Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy Haematologica 75(6): 576-578
Mamaev, N.N.; Mamaeva, S.E.; Ushakova, E.A.; Liburkina, I.L.; Pozniak, E.I. 1986: Results of the study of the activity of bone marrow nucleolar organizers in patients with multiple myeloma Tsitologiia i Genetika 20(2): 91-97
G.Mead, P.; H.D. Carr-Smith; M.Drayson, T.; A.R. Bradwell 2003: Detection of Bence Jones Myeloma and Monitoring of Myeloma Chemotherapy UsingImmunoassays Specific for Free Immunoglobulin Light Chains Clinical Laboratory 49(1-2): 25-27